Skip to main content
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. — Investor Relations & Filings

Ticker · HOWL ISIN · US95075A1079 US Manufacturing
Filings indexed 367 across all filing types
Latest filing 2026-03-27 Annual Report
Country US United States of America
Listing US HOWL

About Werewolf Therapeutics, Inc.

https://werewolftx.com/

Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.

Recent filings

Filing Released Lang Actions
10-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
Annual Report FY 2025
2026-03-27 English
8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
Regulatory Filings
2026-03-27 English
8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer)
Regulatory Filings
2026-02-24 English
8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer)
Regulatory Filings
2026-02-13 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-11 English
8-K Filing
Regulatory Filings
2026-02-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.